Fundamental Data for OSIP

OSI PHARMA(NSDQ:OSIP)

Osi Pharmaceuticals is one of the leading pharmaceutical research and development organizations, commercializing its skills in drug discovery, preclinical research, and drug development. The company has assembled an effective drug discovery and development capability comprised of a talented team of research scientists and business professionals.

# Employees: 514

Address: 41 Pinelawn Road,Melville,NY,USA

Phone: 631 962-2000

Fax: 631 752-3880

Website: www.osip.com

Email: investor_info@osip.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Robert A. Ingram (Chmn.)

Colin Goddard Ph.D. (C.E.O.; Dir.)

Michael G. Atieh (Exec. V.P.; C.F.O.; Chief Acctg. Off.)

Daryl K. Granner M.D. (Dir.)

Morgan G. Browne (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/18/2010

Mean EPS (Next Qtr): $0.41

Mean EPS (Year): $1.26

Mean Estimate(Long Term): $15.20

P/E Ratio(Based on EPS estimate): 25.940

Number of Estimates: 14

Shares Performance

Period	OSIP	Compare to S&P
YTD	-16.03 %	-30.50 %
4 Weeks	1.30 %	0.20 %
12 Weeks	-3.98 %	-9.48 %

Shares Information

Analyst Coverage: Y

Avg Volume: 682876

Shares Outstanding: 58M

Market Cap: $1.90B

52 Week High: $42.32

52 Week Low: $27.47

P/E Ratio: 16.480

PEG Ratio: 1.710

Split: On 1/1/1990 OSIP split by factor of 0.200

Earnings Performance

EPS Growth in Last Quarter: 178.57 %

EPS Growth in Last Year: 39.29 %

Sales Growth in Last Quarter: 12.50 %

Sales Growth in Last Quarter: 17.84 %

Financials

Qtr Book Value: $2.80

Cash Flow/Share: $13.40

Change in Payout Ratio: 0.000

Price/Sales: 4.730